Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions. Bifurcation lesions account...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). This includes both metallic and bioresorbable drug-eluting stents and related clinical trial data.
-
-
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest generation of the company's Xience everolimus-eluting coronary stent system....
-
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at the 2018 meeting of the American College of Cardiology (ACC).
-
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S. Food and Drug Administration (FDA) approval and U.S.
Image courtesy of Hexacath
News | Stents Drug Eluting | May 31, 2018
May 31, 2018 – Late-breaking...
News | Stents Drug Eluting | May 31, 2018
May 31, 2018 — Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-...
News | Stents Bifurcation | May 29, 2018
May 29, 2018 – Medtronic plc announced the initiation of a U.S....
Technology | Stents Drug Eluting | May 25, 2018
May 25, 2018 — Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at the 2018...
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S. Food and Drug...
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently...
News | Antiplatelet and Anticoagulation Therapies | February 13, 2018
February 13, 2018 — Abbott announced the first patient has been enrolled in a...
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s...
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).
Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or...
Technology | Stents Drug Eluting | December 13, 2017
December 13, 2017 — Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug...
The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.
News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting,...
